FDA approves Lexiscan injection for testing of coronary artery disease
CVT Therapeutics Inc. has received FDA approval for its injection for the detection of coronary artery disease . The Lexiscan injection is designed as a pharmacologic stress agent in the testing to detect and characterize coronary artery disease for patients who are unable to undergo adequate exercise stress.
- Yale doctors create a POC testing system
- FDA’s expanded indication for Chembio’s POC testing
- FDA approval to GE Healthcare’s AdreView™
- Scanning for calcium deposits may predict heart disease
